【Medical Companion Travel】National Medical Insurance Bureau: More than 40 rare disease drugs have been included in medical insurance, involving 25 diseases

In order to solve the problem of medication for patients with rare diseases, the 2021 China Rare Disease Conference was held in Beijing on the 18th. The meeting pointed out that in 2018, since the establishment of the National Medical Insurance Bureau, the medical insurance drug list has been dynamically adjusted once a year for four consecutive years, and 507 new drugs and good drugs, including rare disease drugs, have been included in medical insurance, and the scope of drug protection for patients has been continuously expanded and optimized. According to statistics, as of now, there are more than 60 kinds of rare disease drugs approved for listing in China, of which more than 40 have been included in the national medical insurance directory, involving a total of 25 diseases.

Before the hot search of the negotiation video everyone should remember, the negotiator's sentence "every weak group should not be abandoned" moistened the eyes of many people, and finally, in the 2021 medical insurance negotiations, after the unremitting efforts of the National Medical Insurance Bureau, a total of 7 rare disease drugs were successfully negotiated, and the average price drop was 65%.

According to the estimates of relevant institutions, there are about 20 million patients with various rare diseases in China, and more than 200,000 new patients are added every year. In the face of the growing rare disease population, the drug guarantee for the treatment of rare diseases must be continuously accelerated.

The newly revised measures for the administration of drug registration in 2020 make it clear that the State Food and Drug Administration will include innovative drugs and improved new drugs for the prevention and treatment of rare diseases with obvious clinical value, and the State Food and Drug Administration will be included in the priority review and approval procedures, and the rare disease drugs that have been listed overseas and are not listed in China will be completed within 70 days.

According to Chen Shifei, deputy director of the State Food and Drug Administration, the State Food and Drug Administration will issue an announcement on matters related to the review and approval of new overseas drugs that are urgently needed in clinical practice, and select and release three batches of a total of 81 lists of new drugs that are urgently needed abroad, of which more than half of the drugs are rare disease treatment drugs, and encourage enterprises to declare. At present, 26 have been approved for listing through the special channel for new drugs that are urgently needed for clinical use.

In addition, Director Chen also said, "Among all the applications for listed drugs, the review and approval time limit for rare disease drugs is the shortest. ”

In 2021, the State Food and Drug Administration newly approved 10 rare disease drugs such as risperlan oral solution powder for the treatment of rare diseases such as spinal muscular atrophy, filling the gap in domestic related treatment drugs and bringing hope to more patients with rare diseases.

Through the country's access to the negotiations on rare disease drugs, the price of rare disease drugs has been greatly reduced, so that more rare disease patients and families have seen hope, and as the negotiators said, "every weak group should not be abandoned", for the benefit of the people, not to disappoint the mission, the soul bargaining, the hair must be contested, straight to the hearts of the people. Every game of negotiation is to "reduce the pressure" of the medical insurance fund, and it is also to bail out tens of millions of families.